| Overall n | 689 |
|---|
| BMI (mean (sd)) | 27.76 (6.62) |
| Age (mean (sd)) | 62.27 (13.21) |
| Sex = Male (%) | 402 (58.3) |
| ECOG (%) |
| 0 | 185 (31.0) |
| 1 | 272 (45.6) |
| 2 | 113 (19.0) |
| > 2 | 26 (4.4) |
| CCI = 0–1 (%) | 458 (66.7) |
| Cancer (%) |
| Bladder Cancer | 32 (4.9) |
| Head and Neck Carcinoma | 42 (6.5) |
| Melanoma | 184 (28.4) |
| Non-Small Cell Lung Cancer | 152 (23.5) |
| Renal Cell Carcinoma | 65 (10.0) |
| Sarcoma | 21 (3.2) |
| Other | 152 (23.5) |
| Staging (%) |
| 1 | 1 (0.2) |
| 2 | 4 (0.7) |
| 3 | 44 (7.2) |
| 4 | 547 (90.0) |
| Unknown | 12 (2.0) |
| Immune Checkpoint Inhibitors (%) |
| Atezolizumab | 22 (3.2) |
| Durvalumab | 12 (1.7) |
| Durva + Tremelimumab | 6 (0.9) |
| Ipilimumab | 126 (18.3) |
| Nivolumab | 364 (52.8) |
| Nivolumab + Ipilimumab | 37 (5.4) |
| Pembrolizumab | 104 (15.1) |
| Tremelimumab | 3 (0.4) |
| Other | 15 (2.2) |
| ATB within 28 days of ICI (%) | 241 (35.0) |
| CS within 28 days of ICI (%) | 273 (39.6) |
